17. №7. 2019

54 ПРАКТИЧЕСКАЯ МЕДИЦИНА
Том 17, № 7. 2019
коидным рецепторам, блокаторов эпителиальных
натриевых каналов) позволяет достичь медикаментозной
компенсации проявлений первичного
гиперальдостеронизма, предотвратить рецидивирование
гипокалиемических миоплегий и/или уменьшить
связанные со снижением содержания калия в
крови клинические проявления нарушения функционирования
пищеварительной, сердечно-сосудистой
и нервно-мышечной систем.
Первичный гиперальдостеронизм, характеризуясь
клиническим полиморфизмом, определяя
возникновение поражения сердечно-сосудистой,
мочевыделительной систем, нервно-мышечных нарушений,
является комплексной проблемой и требует
мультидисциплинарного подхода, информированности
врачей различного профиля для подбора
адекватной тактики лечения.
Саковец Т.Г.
https://orcid.org/0000-0002-0713-9836
Богданов Э.И.
https://orcid.org/0000-0003-4542-4846
ЛИТЕРАТУРА
1. Vetshev P.S., Podzolkov V.I., Rodionov A.V. et al. Primary
hyperaldosteronism: to the 50th anniversary since Conn's syndrome
has been first described // Issues of Endocrinology. — 2006. —
Vol. 52 (2). – P. 27–35.
2. Kronenberg G.M., Melmed S., Polonskiy K.S. et al. Diseases of
the adrenal cortex and endocrine arterial hypertension. — М.: Reed
Elsevier. — 208 p.
3. Fogari R., Preti P., Zoppi A. et al. Prevalence of primary
hyperaldosteronism among unselected hypertensive patients: a
prospective study based on the use of an aldosterone/renin ratio
above 25 as a screening test // Hypertens. Res. — 2007. — Vol. 30. —
P. 111–117.
4. Rogal E.Y., Beltsevich D.G., Fadeyev V.V. et al. Diagnostics of
primary hyperaldosteronism // Issues of Endocrinology. — 2010. —
Vol. 56 (2). — P. 47–52.
5. Su T.C., Bai C.H., Chang H.Y. et al. Evidence for improved control
of hypertension in Taiwan: 1993-2002 // J Hypertens. – 2008. –
Vol. 26, №3. - P. 600-666.
6. Yen R.F., Wu V.C., Liu K.L. et al. 131I-6b-iodomethyl-19-
norcholesterol SPECT/CT for primary aldosteronism patients with
inconclusive adrenal venous sampling and CT results // J Nucl Med. —
2009. — Vol. 50 (10). — P. 1631–1637.
7. Wu V.C., Wang S.M., Chang C.H. et al. Long term outcome of
Aldosteronism after target treatments // Sci Rep. — 2016. — Vol. 6. —
P. 321–323.
8. Rossi G.P., Cesari M., Cuspidi C. et al. Long-term control of
arterial hypertension andregression of left ventricular hypertrophy
with treatment of primary aldosteronism // Hypertension. — 2013. —
Vol. 62 (1). — P. 62–69.
9. Young W.F. The incidentally discovered adrenal mass // N Engl J
Med. — 2007. — Vol. 356. — P. 601–610.
10. Ma J.T.,Wang C., Lam K.S. et al. Fifty cases of primary
hyperaldosteronism in Hong Kong Chinese with a high frequency of
periodic paralysis. Evaluation of techniques of tumor localization // Q
J Med. — 1986. — Vol. 61. — P. 1021–1037.
11. Wu V.C., Hu Y.H., Er L.K. et al. Case detection and diagnosis
of primary aldosteronisme the consensus of Taiwan Society of
Aldosteronism // J Formos Med AssocZ Taiwan yi zhi. — 2017. —
Vol. 116 (12). — P. 993–1005.
12. Rossi H., Kim A., Prinz R.A. et al. Primary hyperaldosteronism
in the era of laparoscopic adrenalectomy/discussion// Am Surg. —
2002. — Vol. 68 (3). — P. 253.
13. Giacchetti G., Ronconi V., Rilli S. et al. Small tumor size as
favorable prognostic factor after adrenalectomy in Conn’s adenoma //
Eur J Endocrinol. — 2009. — Vol. 160 (4). — P. 639–646.
14. Goldberg S., Solbiati L., Hahn P. et al. Large-volume tissue
ablation with radio frequency by using a clustered, internally cooled
electrode technique: laboratory and clinical experience in liver
metastases // Radiology. — 1998. — Vol. 209 (2). — P. 371–379.
15. Liu S.Y., Ng E.K., Lee P.S. et al. Radiofrequency ablation for
benign aldosterone-producing adenoma: a scarless technique to an
old disease // Ann Surg. — 2010. — Vol. 252 (6). — P. 1058–1064.
16. Liu S.Y.W., Chu C.C.M., Tsui T.K.C. et al. Aldosterone-producing
adenoma in primary aldosteronism: CT-guided radiofrequency
ablationdlong-term results and recurrence rate // Radiology. —
2016. — Vol. 281 (2). — P. 625–634.
17. Inoue H., Nakajo M., Miyazono N. et al. Transcatheter
arterial ablation of aldosteronomas with highconcentration ethanol:
preliminary and long-term results // AJR Am J Roentgenol. — 1997. —
Vol. 168 (5). — P. 1241–1245.
18. Hokotate H., Inoue H., Baba Y. et al. Aldosteronomas:
experience with superselective adrenal arterial embolization in 33
cases // Radiology. — 2003. — Vol. 227 (2). — P. 401–416.
19. Hokotate H., Inoue H., Baba Y. et al. Aldosteronomas:
experience with superselective adrenal arterial embolization in 33
cases // Radiology. — 2003. — Vol. 227 (2). — P. 401–406.
20. Minowada S., Enomoto Y., Korenaga T. et al. CT-guided acetic
acid injection therapy for aldosterone-producing adrenocortical
adenoma: a preliminary report of three cases // Endocr J. — 2000. —
Vol.47 (2). — P. 185–189.
21. Chang F.C. Liu K.L., Huang K.H. et al. Recurrence of primary
aldosteronism after percutaneous ethanol injection // J Formos Med
Assoc. — 2012. — Vol. 111 (3). — P. 176–178.
22. Ma T.K., Szeto C.C. Mineralocorticoid receptor antagonist for
renal protection // Ren Fail. — 2012. — Vol. 34 (6). — P. 810–817.
23. Gomez-Sanchez E.P. Third-generation mineralocorticoid
receptor antagonists: why do we need a fourth? // J Cardiovasc
Pharmacol. — 2016. — Vol. 67 (1). — P. 26–38.
24. Greenblatt D.J., Koch-Weser J. Gynecomastia and impotence:
complications of spironolactone therapy // J Am Med Assoc. — 1973. —
Vol. 223 (1). — P. 82.
25. Bramlage P., Swift S.L., Thoenes M. et al. Non-steroidal
mineralocorticoid receptor antagonism for the treatment of
cardiovascular and renal disease // Eur J Heart Fail. — 2016. —
Vol. 18 (1). — P. 28–37.
26. Deinum J., Riksen N.P., Lenders J.W. Pharmacological treatment
of aldosterone excess // Pharmacol Ther. — 2015. — Vol. 154. —
P. 120–133.
27. De Gasparo M., Joss U., Ramjoue H. et al. Three new epoxyspirolactone
derivatives: characterization in vivo and in vitro // J
Pharmacol Exp Ther. — 1987. — Vol. 240 (2). — P. 650–656.
28. Weinberger M.H., Roniker B., Krause S.L. et al. Eplerenone, a
selective aldosterone blocker, in mild-to-moderate hypertension // Am
J Hypertens. — 2002. — Vol. 15 (8). — P. 709–716.
29. Lim P.O., Young W.F., MacDonald T.M. A review of the medical
treatment of primary aldosteronism // J Hypertens. — 2001. —
Vol. 19 (3). — P. 353–361.
30. Kruse B.A., Carlson R.W. Rapid correction of hypokalemia using
concentrated intravenous potassium chloride infusions // Arch Intern
Med. — 1990. — Vol. 150. — P. 613–617.
31. Tang J. Hypokalemia and Hyperkalemia. In book: Conn's
Current Therapy. — Elsevier Inc., 2019. — P. 327–330.
32. Gahart R.N., Nazareno A.R., Ortega M.Q. Intravenous
Medications. In book: Gahart's. — Elsevier Inc., 2019. — P. 1021–1055.